This page shows the latest Evusheld news and features for those working in and with pharma, biotech and healthcare.
A new study from Oxford University shows that Evusheld is effective in protecting against emerging Omicron variants. ... According to new preclinical data from the University of Oxford, AstraZeneca’s Evusheld, AZD7442, is effective in protecting
This data provides confidence that one easily administered intramuscular dose of Evusheld could provide vulnerable populations with long-lasting protection. ... In addition, Evusheld has been shown to neutralise BA.2, currently the dominant circulating
AstraZeneca’s Evusheld, a long-acting antibody combination, has received a recommendation for marketing authorisation in the European Union (EU). ... Evusheld is authorised for emergency use for pre-exposure prevention of COVID-19 in the US and in six
AstraZeneca (AZ) has announced that its antibody combination treatment Evusheld (tixagevimab co-packaged with cilgavimab) has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). ... Tom Keith Roach, president of AstraZeneca
Unlike other approved antibody therapies, which are approved to treat people who are already infected with COVID-19, Evusheld – a combination of monoclonal antibodies tixagevimab and cilgavimab, formerly known as AZD7442 – ... to establish how
More from news
Approximately 4 fully matching, plus 1 partially matching documents found.
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...